(MENAFN- GlobeNewsWire - Nasdaq) The nasal allergy treatment market is primed for growth due to rising allergic rhinitis cases, innovation in drug delivery, and digital health tech integration. Expanding in the U.S. and China, opportunities abound for diverse drug therapies and strategic partnerships to meet increasing global demand.

Dublin, Oct. 08, 2025 (GLOBE NEWSWIRE) -- The "Nasal Allergy Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)" report has been added to ResearchAndMarkets's offering.
The global nasal allergy treatment market is projected to exhibit robust growth during the forecast period of 2025 to 2032. With increasing prevalence of allergic rhinitis (AR) and growing awareness about allergy management, the market is expected to expand from a valuation of US$ 16 billion in 2025 to US$ 21.2 billion by the end of 2032. This growth reflects a steady compound annual growth rate (CAGR) of 4.10%.
Market Insights
Nasal allergy, commonly referred to as allergic rhinitis, is an inflammatory condition triggered by exposure to airborne allergens and mediated by the immunoglobulin E (IgE). It is one of the most prevalent chronic diseases globally, particularly affecting populations in low- and middle-income countries. Nasal allergy treatment currently commands a dominant share in the global allergy treatment market and continues to grow as pharmaceutical innovations evolve alongside increasing public health initiatives.
Retail pharmacies accounted for a significant share in recent years, owing to the ease of access to over-the-counter medications and self-treatment among consumers. Corticosteroids remain the most widely used treatment option, given their efficacy in managing inflammation and chronic symptoms associated with allergies.
Market Drivers
The rise in nasal allergy cases is attributed to a variety of factors including increased exposure to environmental pollutants, higher tobacco consumption, and changing climatic conditions. Heavy tobacco use, in particular, has been associated with a higher incidence of allergic rhinitis. Additionally, widespread urbanization and indoor living environments contribute to constant exposure to indoor allergens, further exacerbating the issue.
Digital health technologies are transforming the treatment Analysis by enabling self-monitoring and enhancing patient adherence. Mobile applications and electronic diaries are increasingly used to track treatment efficacy, provide reminders, and offer personalized health education. These tools are proving especially beneficial in resource-constrained settings, offering affordable and scalable solutions to enhance patient outcomes.
Business Opportunity
The nasal allergy treatment market presents lucrative opportunities for pharmaceutical manufacturers. Drug developers are focusing on offering a range of drug administration options including nasal sprays, oral tablets, and intraocular solutions to cater to patient preferences. Innovation in bioadhesive drug delivery systems for nasal administration is also gaining traction.
In addition to traditional treatments like antihistamines and corticosteroids, emerging therapies such as placental extract injections and immunotherapies are being investigated to provide longer-term relief. Market players are actively engaged in research and strategic partnerships to enhance their product pipelines and meet rising global demand.
Regional Analysis
The United States continues to lead the global nasal allergy treatment market, driven by high awareness levels, advanced healthcare infrastructure, and the availability of favorable reimbursement policies under Medicare and Medicaid. In 2024, the U.S. accounted for the largest market share due to seasonal allergen exposure and a strong over-the-counter pharmaceutical sector.
China is emerging as a promising market, with increasing incidence of allergic rhinitis due to urbanization and environmental factors. There is an urgent need for preventive and treatment measures, particularly among children, where AR is a significant health risk.
In the United Kingdom, high smoking rates and a considerable patient base suffering from nasal allergies are contributing to market growth. Increased awareness campaigns and availability of non-prescription treatments at retail outlets are supporting the expansion of the market in the region.
Key Players
The nasal allergy treatment market is characterized by a fragmented competitive Analysis with several global and regional players. Key companies are focused on innovation, regulatory approvals, and product expansion to maintain market competitiveness. In recent developments, Glenmark Specialty S.A. received FDA approval for Ryaltris, a prescription nasal spray for allergic rhinitis, while Sanofi's Dupixent received authorization for use in treating chronic rhinosinusitis with nasal polyposis.

• Merck & Co.
• Boehringer Ingelheim
• AstraZeneca
• GlaxoSmithKline PLC
• Sanofi S.A.
• Johnson & Johnson
• Teva Pharmaceutical Industries Ltd.
• Alcon (Novartis AG)
• Stallergenes Greer
• Allergy Therapeutics
• ALK-Abello A/S
• Hanmi Pharmaceutical
• Immunotek
• Regeneron Pharmaceuticals
• Abdi Ibrahim Pharmaceuticals
• Glenmark

Segmentation of the Nasal Allergy Treatment Market

By Treatment:

• Immunotherapy
• Antihistamines
• Decongestants
• Corticosteroids
• Others

By Disease:

• Seasonal Allergic Rhinitis
• Perennial Allergic Rhinitis
• Occupational Allergic Rhinitis

By Route of Administration:

• Oral
• Nasal
• Intraocular
• Intravenous

By Distribution Channel:

• Retail Pharmacies
• Hospital Pharmacies
• e-Commerce

By Region:

• North America
• Latin America
• Europe
• Asia Pacific
• Oceania
• Middle East & Africa (MEA)

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: Laura Wood,Senior Press Manager ... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN08102025004107003653ID1110166987